Hot Stocks
|
Aerojet Rocketdyne (AJRD)… ShowHide Related Items >><< - 03/16/23
- Aerojet Rocketdyne stockholders approve proposed acquisition by L3Harris
- 03/15/23
- L3Harris receives request for more info from FTC over Aerojet deal
- 02/23/23
- Aerojet Rocketdyne begins hiring at new manufacturing facility in Huntsville
- 02/14/23
- Elliott buys NiSource, cuts Aerojet in Q4
- 10:01 Today
- Lockheed Martin, Singapore's DSTA sign collaboration agreement
- 03/24/23
- Lockheed Martin awarded $186.5M U.S. Navy contract modification
- 03/24/23
- Lockheed Martin awarded $474.2M U.S. Navy contract modification
- 03/21/23
- Lockheed Martin awarded $119.98M Navy contract modification
- 01/09/23 Truist
- Aerojet Rocketdyne price target raised to $58 from $45 at Truist
- 12/27/22 Morgan Stanley
- Morgan Stanley says space-related M&A highlight attractiveness of end market
- 12/20/22 JPMorgan
- Aerojet Rocketdyne downgraded to Neutral from Overweight at JPMorgan
- 12/19/22 Baird
- L3Harris downgraded to Neutral at Baird after Aerojet Rocketdyne deal
- 02/21/23 BofA
- F-35 re-engining an underappreciated opportunity for GE, says BofA
- 02/06/23 Credit Suisse
- Lockheed Martin double upgraded to Outperform at Credit Suisse
- 02/06/23 Credit Suisse
- Lockheed Martin upgraded to Outperform from Underperform at Credit Suisse
- 01/30/23 DZ Bank
- Lockheed Martin upgraded to Buy from Hold at DZ Bank
- 02/15/23
- Aerojet Rocketdyne reports Q4 EPS 31c, consensus 59c
- 11/01/22
- Aerojet Rocketdyne reports Q3 adjusted EPS 45c, consensus 44c
- 01/24/23
- Lockheed Martin reports Q4 adjusted EPS $7.79, consensus $7.39
- 01/24/23
- Lockheed Martin sees FY23 EPS about $26.60-$26.90, consensus $26.93
- 01/24/23
- Lockheed Martin reports Q4 EPS $7.40, consensus $7.39
- 01/23/23
- Notable companies reporting before tomorrow's open
- 01/04/23
- Lagging arms production raises concerns over industry consolidation, WSJ report
- 12/18/22
- L3Harris nears $4.7B deal for Aerojet Rocketdyne, Bloomberg reports
- 11/30/22
- Aerojet Rocketdyne deal pursued by GE, L3Harris, Reuters reports
- 11/30/22
- Aerojet Rocketdyne deal pursued by GE, L3Harris, Reuters reports
- 03/07/23
- Biden to propose Pentagon budget of over $835B, Bloomberg says
- 01/13/23
- Biden administration seeks congressional OK for F-16 sale to Turkey, WSJ says
- 01/09/23
- Canada finalizes deal to buy 88 of Lockheed's F-35 fighter, Reuters reports
- 01/06/23
- McCarthy's speaker deal includes $75B defense cut, Bloomberg reports
- 12/19/22
- What You Missed On Wall Street On Monday
- 12/19/22
- What You Missed On Wall Street This Morning
- 12/19/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/19/22
- Fly Intel: Pre-market Movers
- 02/16/23
- What You Missed On Wall Street On Thursday
- 02/16/23
- What You Missed On Wall Street This Morning
- 02/11/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 02/07/23
- What You Missed On Wall Street On Tuesday
- 02/13/23
- Unusually active option classes on open February 13th
- 01/24/23
- Unusually active option classes on open January 24th
- 11/17/22
- Early notable gainers among liquid option names on November 17th
- 10/18/22
- Unusually active option classes on open October 18th
|
Hot Stocks
| ShowHide Related Items >><< - 09:07 Today
- First Citizens 'encouraged' by SVB's strong underwriting
- 09:06 Today
- First Citizens: Capital ratios remains robust after SVB pact
- 04:30 Today
- First Citizens acquires deposits and loans of Silicon Valley Bank
- 03/23/23
- Stifel Financial announces significant expansion of venture banking business
- 03/22/23
- Senators Scott, Warren unveil bipartisan Fed oversight legislation
- 03/22/23
- Stronghold Digital reports no direct exposure to SVB, Signature, Silvergate
- 03/20/23
- WhiteHorse Finance says no exposure to Silicon Valley Bank or Signature Bank
- 03/20/23
- OCC conditionally approves Flagstar to buy, assume deposits of Signature
- 03/24/23 Morgan Stanley
- nCino price target lowered to $27 from $35 at Morgan Stanley
- 03/23/23 Raymond James
- Block short report doesn't include 'bombshell,' says Raymond James
- 03/22/23 BofA
- Regional bank distress gives CME Group a new growth opportunity, says BofA
- 03/20/23 Benchmark
- Aspen Aerogels upgraded to Buy from Hold at Benchmark
- 03/24/23 Morgan Stanley
- nCino price target lowered to $27 from $35 at Morgan Stanley
- 03/22/23 BofA
- Regional bank distress gives CME Group a new growth opportunity, says BofA
- 03/22/23 Raymond James
- New York Community Bancorp resumed with a Strong Buy at Raymond James
- 03/20/23 BofA
- New York Community's Signature deal 'could be a significant positive,' says BofA
- 03/10/23
- Compugen considers exposure to SVB Financial as immaterial
- 01/19/23
- SVB Financial reports Q4 EPS $4.62, consensus $5.27
- 10/20/22
- SVB Financial reports Q3 EPS $7.21, consensus $6.95
- 01/17/23
- Signature Bank reports Q4 EPS $4.65, consensus $4.89
- 10/18/22
- Signature Bank reports Q3 EPS $5.57, consensus $5.41
- 10/17/22
- Notable companies reporting before tomorrow's open
- 10/17/22
- Notable companies reporting before tomorrow's open
|
General news
| ShowHide Related Items >><< - 03/22/23
- Senators Scott, Warren unveil bipartisan Fed oversight legislation
- 03/01/23
- Einhorn says investors should be 'bearish on stocks and bullish on inflation'
- 03/08/23
- Biden to propose 25% billionaire tax, Bloomberg says
- 03/08/23
- Biden to propose 25% billionaire tax, Bloomberg says
- 03/07/23
- Powell tells Congress data from January partly reversed softening trends
- 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 03/22/23
- What You Missed On Wall Street On Wednesday
- 03/21/23
- What You Missed On Wall Street On Tuesday
- 03/21/23
- What You Missed On Wall Street This Morning
- 03/08/23
- What You Missed On Wall Street On Wednesday
- 03/22/23
- Fed says 'additional policy firming may be appropriate'
|
Options
| ShowHide Related Items >><< - 03/16/23
- Sarepta falls 20% after disclosing FDA AdCom meeting to be held for SRP-9001
- 03/16/23
- Sarepta says advisory committee meeting to be held for SRP-9001
- 02/17/23
- Sarepta announces first patient dosed in SRP-9003-102 study
- 02/13/23
- Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4
- 03/22/23 TD Cowen
- Sarepta price target raised to $175 from $125 at TD Cowen
- 03/17/23 RBC Capital
- Sarepta price target lowered to $200 from $226 at RBC Capital
- 03/17/23 Cantor Fitzgerald
- Sarepta price target lowered to $165 from $178 at Cantor Fitzgerald
- 03/17/23 Needham
- Sarepta price target lowered to $160 from $200 at Needham
- 02/28/23
- Sarepta reports Q4 EPS ($1.24), consensus ($1.35)
- 01/09/23
- Sarepta expects to exceed FY22 guidance for net product revenues
- 11/02/22
- Sarepta reports Q EPS (80c), consensus (1.43)
- 03/20/23
- Biotech Alert: Searches spiking for these stocks today
- 03/17/23
- What You Missed On Wall Street On Friday
- 03/17/23
- What You Missed On Wall Street This Morning
- 03/16/23
- Fly Intel: After-Hours Movers
|
Conference/Events
| |
Hot Stocks
| ShowHide Related Items >><< - 02/28/23
- Cigna CEO sells $5.92M in common stock
- 02/02/23
- Managed care stocks pressured after CMS' preliminary Medicare Advantage rates
- 01/12/23
- California AG files suit against drugmakers, PBMs over insulin prices
- 12/06/22
- Walmart to pay $500,000 over workers' compensation prescription procedures
- 03/26/23
- Fly Intel: Top five weekend stock stories
- 03/22/23
- Humana Foundation Board of Directors elects Jones as Chairman
- 03/08/23
- Humana receives FSSA recommendation for healthcare contract
- 02/23/23
- Humana to exit Employer Group Commercial Medical Products business
- 02/23/23 JPMorgan
- Cigna price target lowered to $370 from $378 at JPMorgan
- 02/08/23 Deutsche Bank
- Cigna price target lowered to $348 from $359 at Deutsche Bank
- 02/08/23 SVB Securities
- Cigna price target lowered to $309 from $335 at SVB Securities
- 02/06/23 Loop Capital
- Cigna price target lowered to $320 from $350 at Loop Capital
- 02/28/23 Deutsche Bank
- Humana price target lowered to $562 from $575 at Deutsche Bank
- 02/23/23 BTIG
- Evolent Health price target raised to $45 from $40 at BTIG
- 02/07/23 Truist
- Humana price target lowered to $560 from $580 at Truist
- 02/06/23 Cowen
- Humana price target lowered to $581 from $647 at Cowen
- 02/03/23
- Cigna sees FY23 adjusted EPS $24.60, consensus $24.84
- 02/03/23
- Cigna reports Q4 adjusted EPS $4.96, consensus $4.86
- 02/02/23
- Notable companies reporting before tomorrow's open
- 02/02/23
- Notable companies reporting before tomorrow's open
- 03/02/23
- Humana and Aledade announce 10 year collaboration
- 02/01/23
- Humana sees FY23 adjusted EPS 'at least' $28.00, consensus $28.00
- 02/01/23
- Humana reports Q4 adjusted EPS $1.62, consensus $1.46
- 01/31/23
- Notable companies reporting before tomorrow's open
- 11:32 Today
- Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports
- 01/27/23
- Cigna sues CVS Health, Amy Bricker for violating noncompete, Bloomberg Law says
- 11/29/22
- Managed care company returns will be tough to keep replicating, WSJ says
- 11/07/22
- Walgreens-backed VillageMD close to $9B deal with Summit, WSJ reports
- 11:32 Today
- Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports
- 03/26/23
- Humana stock a bet on healthcare for seniors, Barron's says
- 11/29/22
- Managed care company returns will be tough to keep replicating, WSJ says
- 11/29/22
- Humana to shut down Jupiter, FL, facility, cut 150+ jobs, SFBJ reports
- 02/03/23
- What You Missed On Wall Street On Friday
- 02/03/23
- What You Missed On Wall Street This Morning
- 02/03/23
- Fly Intel: Pre-market Movers
- 01/27/23
- What You Missed On Wall Street This Morning
- 12/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/26/22
- What You Missed On Wall Street This Morning
- 10/26/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/13/23
- Early notable gainers among liquid option names on January 13th
- 01/30/23
- Early notable gainers among liquid option names on January 30th
- 01/19/23
- Early notable gainers among liquid option names on January 19th
- 01/09/23
- Humana put volume heavy and directionally bearish
- 12/16/22
- Humana put volume heavy and directionally bearish
|
Downgrade
| ShowHide Related Items >><< - 03/13/23
- Momentive Global trading resumes
- 03/13/23
- Momentive to be acquired by Symphony Technology Group for $1.5B in cash
- 03/13/23
- Momentive Global trading halted, news pending
- 02/16/23
- Momentive announces workforce reduction of 14%
- 03/14/23 Wells Fargo
- Momentive downgraded to Equal Weight from Overweight at Wells Fargo
- 03/14/23 Craig-Hallum
- Momentive downgraded to Hold from Buy at Craig-Hallum
- 03/14/23 Needham
- Momentive downgraded to Hold from Buy at Needham
- 08/22/22 Wells Fargo
- Momentive price target lowered to $15 from $20 at Wells Fargo
- 02/16/23
- Momentive sees Q1 revenue flat to up 2%, consensus $124.2M
- 02/16/23
- Momentive reports Q4 adjusted EPS 14c, consensus 10c
- 11/03/22
- Momentive sees Q4 revenue $120M-$122M, consensus $124.2M
- 11/03/22
- Momentive reports Q3 EPS 4c, consensus 4c
- 03/14/23
- What You Missed On Wall Street On Tuesday
- 03/14/23
- What You Missed On Wall Street This Morning
- 03/14/23
- Fly Intel: Pre-market Movers
- 03/14/23
- Unusually active option classes on open March 14th
- 01/03/23
- Momentive Global call volume above normal and directionally bullish
- 11/03/22
- Momentive Global options imply 9.8% move in share price post-earnings
- 10/24/22
- Momentive Global put volume heavy and directionally bearish
|
General news
| ShowHide Related Items >><< - 03/22/23
- Senators Scott, Warren unveil bipartisan Fed oversight legislation
- 03/01/23
- Einhorn says investors should be 'bearish on stocks and bullish on inflation'
- 03/08/23
- Biden to propose 25% billionaire tax, Bloomberg says
- 03/08/23
- Biden to propose 25% billionaire tax, Bloomberg says
- 03/07/23
- Powell tells Congress data from January partly reversed softening trends
- 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 03/22/23
- What You Missed On Wall Street On Wednesday
- 03/21/23
- What You Missed On Wall Street On Tuesday
- 03/21/23
- What You Missed On Wall Street This Morning
- 03/08/23
- What You Missed On Wall Street On Wednesday
- 03/22/23
- Fed says 'additional policy firming may be appropriate'
|
Conference/Events
| ShowHide Related Items >><< - 02/23/23
- Arvinas expects cash to fund requirements into 2026
- 12/16/22
- Arvinas appoints Everett Cunningham to board of directors
- 11/22/22
- Arvinas says ARV-471 achieves clinical benefit rate of 38% in evaluable patients
- 11/08/22
- Arvinas expects cash to fund operations multiple years beyond 2024
- 12/07/22
- Olema announces results from Phase 1b dose escalation study of OP-125
- 10/26/22
- Olema Oncology announces preliminary results from OP-1250 trial
- 03/07/23
- Ambrx Biopharma falls -26.7%
- 03/07/23
- Ambrx Biopharma falls -13.4%
- 03/07/23
- Ambrx Biopharma falls -10.9%
- 03/06/23
- Ambrx Biopharma trading resumes
- 03/23/23
- Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements
- 03/21/23
- Kite announces primary OS analysis results of Phase 3 ZUMA-7 study
- 03/20/23
- Gilead exercises option to license Nurix's NX-0479
- 03/20/23
- Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics
- 05:18 Today
- Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints
- 03/23/23
- AstraZeneca says Calquence conditionally approved in China for first indication
- 03/09/23
- AstraZeneca announces ADAURA trial meets secondary endpoint
- 03/09/23
- AstraZeneca announces AEGEAN trial demonstrated statistical significance
- $334.19 /
-1.865 (-0.55%) - 03/22/23
- Roche to collaborate with Lilly on early diagnosis of Alzheimer's disease
- 03/14/23
- Veru says terminating Phase 3 VERACITY trial of sabizabulin
- 03/08/23
- Eli Lilly says primary, secondary endpoints not met in A4 Study
- 03/08/23
- Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older
- 03/09/23 Guggenheim
- Relay Therapeutics price target lowered to $28 from $45 at Guggenheim
- 03/07/23 H.C. Wainwright
- Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright
- 02/02/23 Oppenheimer
- Relay Therapeutics initiated with an Outperform at Oppenheimer
- 01/19/23 JMP Securities
- Relay Therapeutics price target lowered to $28 from $38 at JMP Securities
- 03/18/23 Citi
- Arvinas price target raised to $77 from $72 at Citi
- 02/23/23 Capital One
- Arvinas remains one of the best biotechs to own, says Capital One
- 01/17/23 Truist
- Arvinas price target lowered to $65 from $100 at Truist
- 01/12/23 Capital One
- Arvinas pullback a buying opportunity, says Capital One
- 03/10/23 H.C. Wainwright
- Olema Oncology price target raised to $15 from $12 at H.C. Wainwright
- 02/22/23 Credit Suisse
- Olema Oncology initiated with an Outperform at Credit Suisse
- 07/06/22 Canaccord
- Olema Oncology assumed with a Buy at Canaccord
- 06/09/22 H.C. Wainwright
- H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data
- 03/03/23 Baird
- Ambrx Biopharma price target raised to $11 from $4 at Baird
- 10/19/22 Baird
- Ambrx Biopharma price target lowered to $4 from $8 at Baird
- 09/21/22 Baird
- Ambrx Biopharma price target lowered to $8 from $16 at Baird
- 04/07/22 Baird
- Baird starts Ambrx Biopharma with Outperform, $16 price target
- 03/20/23 Oppenheimer
- Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news
- 03/13/23 Stifel
- Arcellx initiated with a Buy at Stifel
- 02/14/23 Mizuho
- Gilead price target raised to $101 from $88 at Mizuho
- 02/10/23 Cowen
- Gilead price target raised to $95 from $90 at Cowen
- 03/15/23 Berenberg
- AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
- 03/07/23 Guggenheim
- Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
- 03/07/23 Evercore ISI
- Mineralys Therapeutics initiated with an Outperform at Evercore ISI
- 02/21/23 UBS
- AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
- $334.19 /
-1.865 (-0.55%) - 03/22/23 Stifel
- Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data
- 03/17/23 Stifel
- Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
- 03/13/23 Wells Fargo
- Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
- 03/13/23 Wells Fargo
- Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
- 11/03/22
- Relay Therapeutics reports Q3 EPS (76c), consensus (71c)
- 02/23/23
- Arvinas reports Q4 EPS ($1.56), consensus ($1.22)
- 11/08/22
- Arvinas reports Q3 EPS ($1.24), consensus ($1.13)
- 03/09/23
- Olema Oncology reports Q4 EPS (65c), consensus (65c)
- 02/02/23
- Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73
- 02/02/23
- Gilead reports Q4 adjusted EPS $1.67, consensus $1.49
- 02/02/23
- Notable companies reporting after market close
- 12/20/22
- Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c
- 02/09/23
- AstraZeneca sees FY23 core EPS up high single to low double-digit percentage
- 02/09/23
- AstraZeneca reports Q4 core EPS $1.38, consensus $1.35
- 11/10/22
- AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage
- 11/10/22
- AstraZeneca reports Q3 core EPS $1.67, YTD core EPS $5.28
- $334.19 /
-1.865 (-0.55%) - 03/09/23
- Precision BioSciences reports Q4 EPS (26c), consensus (21c)
- 02/02/23
- Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30
- 02/02/23
- Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78
- 02/01/23
- Notable companies reporting before tomorrow's open
|
Options
| ShowHide Related Items >><< - 11/21/22 B. Riley
- Seabridge Gold price target raised to $60 from $57 at B. Riley
- 10/25/22 B. Riley
- Seabridge Gold price target lowered to $57 from $105 at B. Riley
- 03/20/23
- Seabridge Gold options imply 2.0% move in share price post-earnings
|